不同剂量艾多沙班对非瓣膜性老年房颤患者肝肾功能的影响  

Effects of different doses of Edoxaban on liver and kidney function in elderly patients with nonvalvular atrial fibrillation

作　　者：卢旭升[1] 许贤彬[1] 林旭城[1] 胡恺[1] 陆沛杰 林锐波[1] 陈尔周 LU Xusheng;XU Xianbin LIN Xucheng;HU Kai;LU Peijie;LIN Ruibo;CHEN Erzhou(Department of Cardiology,Chaozhou Central Hospital,Chaozhou 521000,Guangdong,China)

机构地区：[1]潮州市中心医院心内科,广东潮州521000

出　　处：《广州医科大学学报》2024年第1期45-49,共5页Academic Journal of Guangzhou Medical University

摘　　要：目的:探究不同剂量艾多沙班对非瓣膜性老年房颤患者肝肾功能的影响。方法:选取我院2022年1月到2023年6月的118例非瓣膜性老年房颤患者,按照随机数字法分为A组(n=59)、B组(n=59),其中A组患者给与大剂量(60 mg/d)艾多沙班进行治疗,B组患者给与小剂量(30 mg/d)艾多沙班进行治疗,再按SHARE-FI评分将A组患者分为强健A组(n=30)、衰弱前期A组(n=11)、衰弱A组(n=18);将B组分为强健B组(n=31)、衰弱前期B组(n=12)、衰弱B组(n=16)。评估强健A组与强健B组,衰弱前期A组与衰弱前期B组,衰弱A组与衰弱B组肝肾功能变化。结果:治疗前后强健A组与强健B组ALT、BUN、Scr均无明显差异(P>0.05);治疗前衰弱前期A组与B组ALT、BUN、Scr无明显差异(P>0.05),治疗后衰弱前期A组ALT、BUN、Scr明显高于衰弱前期B组(P<0.05);治疗前衰弱A组与B组ALT、BUN、Scr无明显差异(P>0.05),治疗后衰弱A组ALT、BUN、Scr明显高于衰弱前期B组(P<0.05)。结论:大剂量(60 mg/d)、小剂量(30 mg/d)艾多沙班对身体强健的非瓣膜性老年房颤患者肝肾功能的影响相当;而大剂量艾多沙班对衰弱前期、衰弱期患者肝肾功能的影响较小剂量艾多沙班大,因而可给予衰弱前期、衰弱期患者小剂量艾多沙班来减少对其肝肾功能的损伤。Objective:To investigate the effects of different doses of Edoxaban on liver and kidney function in elderly patients with nonvalvular atrial fibrillation.Methods:A total of 118 elderly patients with nonvalvular atrial fibrillation in our hospital from January 2022 to June 2023 were selected and divided into group A(n=59)and group B(n=59)according to random number method.Patients in group A were treated with high-dose(60 mg/d)Edoxaban,and patients in group B were treated with low-dose(30 mg/d)Edoxaban.Group A was then divided into robust group A(n=30),pre-debilitation group A(n=11)and debilitation group A(n=18)according to SHARE-FI score.Group B was divided into robust group B(n=31),pre-asthenic group B(n=12),and asthenic group B(n=16).The changes of liver and kidney function in robust group A and robust group B,pre-asthenic group A and pre-asthenic group B,asthenic group A and asthenic group B were evaluated.Results:There were no significant differences in ALT,BUN and Scr between healthy group A and healthy group B before and after treatment(P>0.05).There were no significant differences in ALT,BUN and Scr between group A and group B before treatment(P>0.05),but ALT,BUN and Scr in group A were significantly higher than those in group B after treatment(P<0.05).There were no significant differences in ALT,BUN and Scr between group A and group B before treatment(P>0.05).ALT,BUN and Scr in group A after treatment were significantly higher than those in group B before treatment(P<0.05).Conclusion:High-dose(60 mg/d)and low-dose(30 mg/d)Edoxaban have similar effects on liver and kidney function in healthy elderly patients with nonvalvular atrial fibrillation.The effect of large dose of Edoxaban on liver and kidney function in patients with preasthenia and asthenia stage is smaller,so small dose of Edoxaban can be given to patients with pre-asthenia and asthenia stage to reduce the damage to liver and kidney function.

关 键 词：艾多沙班 非瓣膜性老年房颤患者 肝肾功能 

分 类 号：R541.9[医药卫生—心血管疾病]